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ABSTRACT Leukocyte transendothelial migration into inﬂamed areas is regulated by the integrity of endothelial cell junctions
and is stabilized by adhesion molecules including junctional adhesion molecule-A (JAM-A). JAM-A has been shown to participate
in homophilic interactions with itself and in heterophilic interactions with leukocyte function-associated antigen-1 (LFA-1) via its
ﬁrst and second immunoglobulin domains, respectively. Using competitive binding assays in conjunction with atomic force
microscopy adhesion measurements, we provide compelling evidence that the second domain of JAM-A stabilizes the homo-
philic interaction because its deletion suppresses the dynamic strength of the JAM-A homophilic interaction. Moreover, binding
of the LFA-1 inserted domain to the second domain of JAM-A reduces the dynamic strength of the JAM-A homophilic interaction
to the level measured with the JAM-A domain 2 deletion mutant. This ﬁnding suggests that LFA-1 binding cancels the stabilizing
effects of the second immunoglobulin domain of JAM-A. Finally, our atomic force microscopy measurements reveal that the
interaction of JAM-A with LFA-1 is stronger than the JAM-A homophilic interaction. Taken together, these results suggest that
LFA-1 binding to JAM-A destabilizes the JAM-A homophilic interaction. In turn, the greater strength of the LFA-1/JAM-A complex
permits it to support the tension needed to disrupt the JAM-A homophilic interaction, thus allowing transendothelial migration to
proceed.INTRODUCTION
The migration of leukocytes from the blood stream into
surrounding tissues is a critical process during immune
surveillance as well as inflammatory disease states such as
atherosclerosis (1,2). During inflammatory conditions,
leukocytes accumulate at the site of injury by first rolling
on the endothelium and then undergoing firm adhesion after
their activation in response to chemokines (1). These pro-
cesses are mediated by adhesion molecules. Selectins have
been shown to mediate cell rolling. Both integrins and immu-
noglobulin superfamily members, including the intercellular
adhesion molecule-1 (ICAM-1) and the vascular cell adhe-
sion molecule-1 (VCAM-1), mediate firm adhesion of the
leukocyte to the endothelium (3). This process is followed
by the subsequent migration of the leukocytes across the
endothelium.
Transendothelial migration (TEM) of leukocytes into
inflamed areas takes place mainly via the paracellular path-
way occurring through the junction located between adjacent
endothelial cells. Recent reports (4,5) also confirmed the oc-
currence of migration via the transcellular pathway occurring
through the body of the actual cell. The former and more
predominant pathway is regulated by the integrity of the
endothelial cell junctions, which are stabilized by many mol-
ecules (1,6). These molecules include platelet endothelial
cellular adhesion molecule-1 (PECAM-1), the junctional
adhesion molecule (JAM) family of receptors, and CD99.
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0006-3495/09/01/0285/9 $2.00This work focuses on JAM-A, a member of the JAM
family of receptors that also includes JAM-B, JAM-C,
JAM4, and JAML (7). The role of JAM-A was first impli-
cated in transmigration by the finding that both in vitro
and in vivo leukocyte transmigration were inhibited by an
anti-JAM-A monoclonal antibody (8,9). JAM-A, also known
as JAM-1 or F11R, belongs to the immunoglobulin super-
family of receptors. It is expressed as a dimer on the surface
of circulating cells but is predominantly present in endothe-
lial and epithelial tight junctions of many different tissues
(8,10). JAM-A consists of an intracellular PDZ-domain
binding motif, a transmembrane segment, and two extracel-
lular immunoglobulin (Ig) domains. The PDZ-domain
binding motif has been shown to associate with the tight
junction components occludin, ZO-1, and cingulin and is in-
volved in cell signaling (11,12). The first of these two Ig do-
mains, the membrane-distal Ig domain, is involved in homo-
philic binding to another JAM-A receptor. This binding can
take place across opposing endothelial cells, which comprise
the tight junction (in trans), or between adjacent receptors
during dimer formation (in cis) (13,14). During leukocyte
TEM, the homophilic transendothelial interactions between
these receptors must be disrupted to enable a migrating leu-
kocyte to pass through the junction (10).
Previously, it was demonstrated that JAM-A can also
interact with leukocyte function-associated antigen-1
(LFA-1) via its second membrane-proximal Ig domain
(15,16). Integrin LFA-1 is an ab heterodimeric transmem-
brane glycoprotein expressed on the surface of leukocytes
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early events of leukocyte TEM. After inflammation, JAM-A
is redistributed to the apical portion of the junction, allowing
for leukocyte recruitment possibly via a haptotactic gradient
(15). However, its role in the underlying mechanism of this
process remains ill-defined. It has been postulated that during
TEM a trimeric complex forms between LFA-1 on the mi-
grating leukocyte and a junctional JAM-A complex formed
in trans (15,18). For TEM to proceed, the JAM-A homo-
philic interaction must eventually be broken, leading to the
loosening of junctional contacts and allowing the leukocyte
to migrate.
To our knowledge, the second domain of JAM-A has
been implicated only in the heterophilic interaction with
LFA-1. Using competitive binding assays in conjunction
with atomic force microscopy (AFM), we provide com-
pelling evidence for the role of the second domain of
JAM-A in stabilizing the JAM-A homophilic interaction.
We postulate that the binding of LFA-1 to the second
domain of JAM-A expressed on the endothelium may
be the mechanism through which the JAM-A homophilic
interactions formed across the endothelial junction are
weakened.
METHODS
Cells and reagents
The Jurkat and Chinese hamster ovary (CHO) cell lines were maintained in
continuous culture in Roswell Park Memorial Institute 1640 and Dulbec-
co’s modified Eagle’s F-12 media, respectively. Both cultures were sup-
plemented with 10% heat-inactivated fetal calf serum (Irvine Scientific,
Santa Ana, CA), penicillin (50 U/mL; Gibco BRL, Grand Island, NY),
and streptomycin (50 mg/mL, Gibco BRL) and were expanded on a
3-day cycle. Recombinant soluble human JAM-A was generated as previ-
ously described (16,19). JAM-A contains a cleavage site for tobacco etch
virus (TEV) protease between the JAM-A and Fc domains. After digestion
of JAM-A with TEV protease, the JAM-A extracellular domain was puri-
fied by affinity and anion exchange chromatography. JAM-A$D1 and
JAM-A$D2 were generated accordingly. Rabbit polyclonal antibody
against JAM-A was generated by immunizing rabbits with human
JAM-A$D1. The isolated extracellular domain of JAM-A was biotinylated
using LC-NHS-(þ)-biotin (Molecular Biosciences, Boulder, CO) accord-
ing to manufacturer’s instructions. Antibody against LFA-1 (clone
TS1/22) was purified from culture supernatant of TS1/22 hybridoma cells
(American Type Culture Collection, Manassas, VA) by protein A affinity
chromatography.
Solid-phase binding assay
Microtiter wells (Maxisorp; Nunc, Roskilde, Denmark) were coated with
JAM-A (10 mg/mL) or bovine serum albumin (BSA; 0 mg/mL) in 10 mM
Tris, pH 9.0, and then blocked with 3% BSA. Binding of JAM-A$biotin
to immobilized JAM-A was carried out in binding buffer (Tris-buffered
saline (TBS), 0.5% BSA, 1 mM Mg2þ, 1 mM Ca2þ) containing increasing
concentrations of JAM-A extracellular domain, JAM-A$D1, JAM-A$D2, or
the Fab negative control (AbD Serotec, Du¨sseldorf, Germany) for 2 h at
room temperature. After washing with wash buffer (TBS, 0.05% Tween),
bound JAM-A$biotin was detected with peroxidase-conjugated streptavidin
and quantified using the tetramethylbenzidine substrate reagent kit (Vector
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tracted to calculate specific binding.
CHO cell adhesion assay
CHO cell adhesion assays were carried out as previously described (16)
using CHO cells with a stable expression of human JAM-A or transfected
with vector control. Microtiter wells (Maxisorp; Nunc) were coated with
JAM-A (15 mg/mL) or BSA (15 mg/mL) in 10 mM Tris, pH 9.0, overnight
at 4C and then blocked with 0.5% BSA in phosphate-buffered saline (PBS)
for 1 h at room temperature. CHO transfectants were labeled with BCECF-
AM and allowed to adhere for 30 min at 37C in binding buffer (Hank’s
balanced salt solution, 1 mM Mg2þ, 1 mM Ca2þ, 10 mM Hepes, pH 7.4).
Some wells were preincubated with open inserted (I)-domain, wild-type
I-domain, polyclonal antibody (pAb) anti-JAM-A, or soluble JAM-A at
10 mg/mL. Nonadherent cells were removed by washing twice with binding
buffer, and the fluorescence of input and adherent cells was determined with
a fluorescence plate reader (Tecan, Crailsheim, Germany). Background
binding to BSA was negligible and subtracted.
Protein immobilization
A 20 mL aliquot of JAM-A or JAM-A$D2 at 50 mg/mL (single-molecule
experiments) or 100 mg/mL (whole-cell experiments) in 0.1 M NaHCO3
(pH 8.6) was adsorbed overnight at 4C on the center of a 35 mm tissue
culture dish (Falcon 353001; Becton Dickinson Labware, Franklin Lakes,
NJ). Unbound protein was removed by washing with PBS (10 mM
PO4
3, 150 mMNaCl, pH 7.3). The exposed surface of the dish was blocked
using 0.01% BSA (Sigma, St. Louis, MO) in PBS to eliminate nonspecific
binding to the dish surface. One coated dish was used to complete each AFM
experiment.
AFM measurements of adhesion forces
AFM force measurements were carried out on an apparatus designed to be
operated in the force spectroscopy mode (20–24). Jurkat cells were attached
to the AFM cantilever by concanavalin A (Con A)-mediated linkages that
were prepared as described previously (24).
A single Jurkat cell was attached to the cantilever by positioning the end
of the Con A functionalized cantilever above the center of the cell and
carefully lowering it onto the cell for ~1 s. When attached, the cell was
positioned right behind the AFM tip of the cantilever as shown in Fig. 5
A (24,25). To obtain multiple-bond interactions between the Jurkat cell
and the immobilized protein, an indentation force of ~200 pN and a contact
time of 2 s were used. The experiments were carried out at a cantilever
retraction rate of 5 mm/s at 25C, as previously described (26). Approxi-
mately 50 measurements were acquired in each experiment.
Alternately, JAM-A receptors were cross-linked to the AFM cantilever.
To do so, each cantilever was washed in nanopure water for ~1 min, irradi-
ated with ultraviolet rays for 5 min, transferred into 2% 3-aminopropyl trie-
thoxysilane in acetone, washed five times in nanopure water, transferred
into 0.1% glutaraldehyde in 0.1 M PBS for 30 min at room temperature,
washed five times in 0.1 M PBS, and coated with 100 mg/mL of JAM-A,
JAM-A$D1, or JAM-A$D2. The cantilevers were incubated overnight at
4C. Before use, each cantilever was blocked by soaking in 0.01% BSA
in TBS for 20 min. Experiments were carried out in TBS buffer. The
open I-domain was used at a concentration of 50 mg/mL.
Measurements of unitary LFA-1/JAM-A$D2, JAM-A/JAM-A, and JAM-
A/JAM-A$D1 unbinding forces were obtained under conditions that mini-
mized contact between the Jurkat cell or JAM-A receptors on the cantilever
tip and the substrate. An adhesion frequency of< 30% in the force measure-
ments ensured that there was a > 85% probability that the adhesion events
were mediated by single bonds. Data were corrected for hydrodynamic drag
(27,28). The damping coefficient is the slope of the linear fit of the change in
hydrodynamic drag force versus cantilever speed and is ~10 pN$s/mm for
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cell. Approximately 3000 measurements were typically acquired over 6 to
8 h for each experiment.
RESULTS
The deletion of the second domain of JAM-A
weakens the JAM-A homophilic interaction
Solid-phase binding assays were conducted to compare the
effectiveness of JAM-A and JAM-A$D1, which is a deletion
mutant missing the second domain of JAM-A, in binding to
JAM-A. To our knowledge, only the first domain of JAM-A
is required for the JAM-A homophilic interaction, and so we
expected the JAM-A$D1 mutant to be equally as effective as
JAM-A in competing for JAM-A binding. In these experi-
ments, JAM-A$biotin was allowed to bind to immobilized
JAM-A, and specific binding was analyzed in the presence
of increasing concentrations of unlabeled inhibitor (Fig. 1).
If the JAM-A$biotin was effectively displaced by an
FIGURE 1 Solid-phase binding assays. (A) Specific binding of JAM-A$
biotin to immobilized JAM-A was analyzed in the presence of increasing
concentrations of unlabeled JAM-A (circle), JAM-A$D1 (square), and a
Fab control (solid circle). (B) Specific binding of JAM-A$biotin to immo-
bilized JAM-A was analyzed in the presence of increasing concentrations
of unlabeled JAM-A$D2 (square) and a Fab control (solid circle). The frac-
tion of bound ligand is given as mean5 SE of four separate experiments in
each case.inhibitor, a decrease in the percentage of bound
JAM-A$biotin ligand was observed. This decrease was
very pronounced when JAM-A was used for inhibition but
significantly less so when the JAM-A$D1 mutant was used
for inhibition (Fig. 1 A). Inhibition was not observed with
JAM-A$D2, which is a deletion mutant missing the first
domain, or the Fab negative control (Fig. 1 B). The dimin-
ished level at which the JAM-A$D1 mutant competed for
JAM-A binding was surprising, and indicated that the
presence of the second domain may be important for the
JAM-A homophilic interaction.
To specifically address the potential impact that the
absence of the second domain of JAM-A has on the actual
strength of the JAM-A homophilic interaction, we used
AFM techniques. Single-molecule AFM adhesion measure-
ments were conducted to confirm that the observed decrease
of adhesion strength was the result of domain 2 deletion.
In these experiments, JAM-A protein was cross-linked
to the AFM cantilever tip and allowed to adhere to either
the JAM-A or the JAM-A$D1 substrate. As described in
Methods, these measurements were acquired at an adhesion
frequency of 30% to ensure that measurements of single
JAM-A interactions were obtained. In control experiments,
anti-JAM-A antibody further reduced the adhesion fre-
quency by 70% for both interactions and by > 80% when
JAM-A adhesion was measured on BSA. The representative
AFM force scans of the JAM-A homophilic interaction are
shown in Fig. 2 A. The force jump shown in the third and
sixth scans of the retract trace represents the unbinding force
(fu). The system spring (ks) is determined from the slope of
the force-distance curve and is used to calculate the loading
rate of each measurement. The loading rate is the product of
the system spring and the rate of cantilever retraction. The
measurements were conducted at increasing loading rates,
which was achieved by varying the rate of cantilever retrac-
tion. It is important to study receptor-ligand complexes at
a range of loading rates because they might respond differ-
ently to pulling forces. Such differences in response to an ap-
plied pulling force were observed for a number of receptor-
ligand pairs, namely, VLA-4/VCAM-1, selectin/sialyl Lewis
X, and LFA-1/ICAM-1 and -2 (29–32). All adhesion forces
were sorted according to their respective loading rates and
compiled into force histograms. Representative histograms
for the JAM-A/JAM-A interaction are shown in Fig. 2 B.
The peak unbinding force increased with loading rate (rf).
Using the unbinding forces from the peaks of all force histo-
grams, we generated the dynamic force spectra of the JAM-
A/JAM-A and JAM-A/JAM-A$D1 interactions. The dy-
namic force spectra of unbinding forces for a loading rate
range of ~2000–100,000 pN/s are shown in Fig. 2 C. The av-
erage unbinding forces acquired for JAM-A$D1 were
significantly lower than those acquired with JAM-A (Fig. 2
C). These results confirm that the second domain must
play an important role in stabilizing the JAM-A homophilic
interaction.
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domain 2 of JAM-A stabilizes the JAM-A homophilic inter-
action or if it is involved in actually binding to JAM-A.
Single-molecule AFM adhesion studies were conducted
for the JAM-A$D2/JAM-A, JAMA$D2/JAM-A$D1, and
JAM-A$D2/JAM-A$D2 interactions. Specific interactions
were not observed for any of these interactions as confirmed
by anti-JAM-A$D1 and anti-JAM-A$D2 antibodies. This
finding is a strong indication that the second domain of
JAM-A must be involved in stabilizing the JAM-A homo-
philic interaction, because it does not bind to either itself
or domain 1 of JAM-A.
FIGURE 2 Single-molecule AFM measurements of the JAM-A/JAM-A
and JAM-A/JAM-A$D1 interactions. (A) Single-molecule adhesion force
scans of the JAM-A homophilic interaction. Adhesion was seen in the
second and fifth scans. fu is the unbinding force, and ks represents the system
spring. (B) Force histograms of measurements sorted according to loading
rate (rf). Representative force histograms for loading rates of 2805 5 37
pN/s and 9017 5 102 pN/s are shown. (C) Dynamic force spectrum of
the JAM-A/JAM-A (open circle) and JAMA.D1/JAM-A (black circle) inter-
actions. Individual forces were acquired at a loading rate range of ~2000–
100,000 pN/s, sorted according to loading rate, and compiled into force
histograms. Each data point in the dynamic force spectrum corresponds to
the peak of each force histogram. The error for both loading rate and unbind-
ing force is the standard error of at least three separate experiments.
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As discussed previously, LFA-1 has been shown to bind to
the second domain of JAM-A (15). We postulated that this
binding may interfere with the potential stabilizing effects
of the second domain of JAM-A, thus weakening the
JAM-A homophilic interaction. To determine the effects of
the LFA-1 binding, we measured JAM-A homophilic
adhesion in its presence and absence. The I-domain of
LFA-1, which has been shown to contain the binding site
for JAM-A (16), was used as a surrogate for native LFA-1
in our adhesion assays and our AFM measurements.
We first conducted adhesion assays of CHO transfectants
to JAM-A (Fig. 3). Adhesion to JAM-A was assessed using
CHO cells transfected with vector only (CHO/vector, white
bars) and with JAM-A (CHO/JAM-A, black bars). The vec-
tor controls exhibited little binding to JAM-A substrate. The
binding of the CHO/JAM-A cells was measured in the pres-
ence of both the wild-type and open I-domains. The open
I-domain is a soluble recombinant protein that contains
disulfide bonds that lock it in a permanent state of high affin-
ity (33). CHO/JAM-A cells were allowed to bind to JAM-A
and, after a wash with binding buffer, 22.8 5 2% of input
cells remained bound (Fig. 3). In the presence of the open
I-domain, adhesion of CHO/JAM-A cells was reduced by
> 60% to 8.7 5 1.2%. This large reduction in adhesion
was similar to that observed after the addition of the JAM-A
antibody (9.35 2.2%) (Fig. 3). These results alone suggest
that the binding of LFA-1 weakens the JAM-A homophilic
interaction.
Our single-molecule AFM adhesion studies further con-
firmed the results observed in the CHO cell adhesion assay.
FIGURE 3 Adhesion of CHO transfectants to immobilized JAM-A. CHO
cells transfected with JAM-A or vector control were allowed to adhere to
JAM-A. Cell culture plate wells were incubated with open I-domain,
wild-type (wt) I-domain, pAb anti-JAM-A, or soluble JAM-A. Cell adhesion
is represented as the percentage of total added cells. Data are presented as
mean5 SE of three separate experiments.
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I-domain blocked or modulated the JAM-A homophilic
interaction. JAM-A was cross-linked to the cantilever tip
and allowed to interact with immobilized JAM-A in the pres-
ence and absence of the open I-domain. We used the open
I-domain because it had the greatest impact on the JAM-A
homophilic interaction in the adhesion assays. Fig. 4 A
FIGURE 4 The effect of the open I-domain on the JAM-A homophilic in-
teraction. (A) Dynamic force spectra of JAM-A/JAM-A (open circle) and
JAM-A/JAM-A in the presence of the open I-domain (open square). (B) Dy-
namic force spectra of the JAM-A$D1/JAM-A (black circle) interaction and
JAM-A/JAM-A$D1 (gray square) in the presence of the open I-domain. (C)
Overlay of data from A and B: JAM-A/JAM-A (open circle) and JAM-A/
JAM-A in the presence of the open I-domain (open square), and JAM-
A$D1/JAM-A (black circle). In each dynamic force spectrum, the error
for both loading rate and unbinding force is the standard error of at least
three separate experiments.shows the dynamic force spectrum of the JAM-A homophilic
interaction measured in the absence and presence of the open
I-domain. A significant decrease of ~20 pN was observed in
the average unbinding force in the presence of the open I-do-
main throughout the dynamic force spectrum. In addition,
the adhesion frequency decreased 20% after the addition of
the open I-domain. These experiments were repeated using
JAM-A$D1, which lacks the second domain where LFA-1
binding takes place. The dynamic force spectra for the
JAM-A/JAM-A$D1 interaction in the absence and presence
of the open I-domain are shown in Fig. 4 B. As expected, the
two force spectra overlapped. No change was observed in the
average unbinding force in the presence of the open I-do-
main for the mutant JAM-A. Interestingly, binding of the
LFA-1 I-domain to JAM-A suppressed the dynamic strength
of the JAM-A homophilic interaction to the level that was
measured with JAM-A$D1 (Fig. 4 C). This finding
suggests that binding of LFA-1 to the second Ig domain of
JAM-A canceled its stabilizing effects and led to the lower
adhesion forces measured for the JAM-A homophilic inter-
action.
The heterophilic interaction of LFA-1 with JAM-A
is stronger than the homophilic JAM-A interaction
For TEM to proceed, the heterophilic LFA-1/JAM-A interac-
tion between the leukocyte and endothelium must prevail,
while the junctional JAM-A homophilic contacts are disrup-
ted. Therefore, we postulated that the heterophilic LFA-1/
JAM-A complex may be stronger enabling it to persevere,
while the homophilic JAM-A linkages are disrupted. To de-
termine if this were the case, we compared the dynamic
strength of the JAM-A homophilic complex to its hetero-
philic complex with LFA-1.
To measure the adhesion strength of the LFA-1/JAM-A
complex, Jurkat cells expressing LFA-1 on the cantilever
tip were allowed to adhere to JAM-A on the sample dish
(Fig. 5 A). Since human JAM-A is expressed on lymphocyte
sets, we conducted these experiments with the JAM-A$D2
deletion mutant, which is missing the first JAM-A-binding
domain. We conducted whole-cell AFM adhesion studies be-
fore proceeding with the single-molecule studies to confirm
the specificity of this interaction. Representative whole-cell
adhesion force scans from these experiments are shown in
Fig. 5 B. Each measurement consisted of an approach trace
(Fig. 5 B, top trace of the first force scan) during which
the cantilever and cell were lowered onto the substrate. Con-
tact was made, thus allowing the LFA-1/JAM-A bonds to
form. Finally, the cell was withdrawn from the substrate,
which allowed all the interactions to break, which is repre-
sented by the force jumps in the retract trace (Fig. 5 B, bot-
tom trace of the first force scan). The measurements were
conducted with untreated Jurkat cells and in the presence
of antibodies to confirm specificity. Adhesion strength was
compared by calculating the work of deadhesion, which is
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the adhesive contacts. The work of deadhesion is calculated
by integrating the adhesive force over the distance traveled
FIGURE 5 (A) Schematic representation of the experimental setup used to
conduct Jurkat AFM cell adhesion studies. The LFA-1-expressing Jurkat
cell was attached to the AFM cantilever and allowed to interact with
JAM-A$D2 on the sample petri dish. (B) Whole-cell AFM adhesion mea-
surements of Jurkat cells on JAM-A$D2 without treatment, in the presence
of antibodies against JAM-A$D2 or LFA-1 (TS1/22), and on BSA. The
shaded area represents the work of deadhesion. (C) The average calculated
work of deadhesion from AFM whole-cell adhesion measurements of Jurkat
cells on JAM-A$D2 without treatment, in the presence of anti-JAM-A$D2
antibody, TS1/22 antibody (anti-LFA-1), and Jurkat cells on BSA. The error
is the standard error of three separate experiments. (D) Dynamic force
spectra of the LFA-1/JAM-A$D2 (diamond) and JAM-A/JAM-A (circle)
unbinding forces were acquired for a loading rate range of ~500–100,000
pN/s. The error for both loading rate and unbinding force is the standard
error of at least three separate experiments.
Biophysical Journal 96(1) 285–293by the cantilever. The shaded area under the top force scan
in Fig. 5 B represents the work of deadhesion. The average
work of deadhesion for these experiments was 1.845 0.28
 1016 J for untreated cells (Fig. 5 C). It decreased signifi-
cantly by 73% (to 4.92 5 0.64  1017 J) after treatment
with an antibody directed against the second domain of
JAM-A, and it decreased by 79% (to 3.915 0.54  1017
J) after treatment with an antibody directed against the I-do-
main of LFA-1 (TS1/22). These results confirmed that the
LFA-1/JAM-A interaction supported the observed adhesion.
We then compared the strength of the LFA-1/JAM-A
interaction with the JAM-A/JAM-A interaction by conduct-
ing single-molecule force measurements. The JAM-A/JAM-
A measurements were conducted as described previously.
The LFA-1/JAM-A measurements were conducted in the
same manner as the whole-cell adhesion studies were
conducted. LFA-1-expressing Jurkat cells were attached to
the cantilever tip, and JAM-A$D2 was coated on the sample
dish. Adhesion frequency was reduced to ~30% by a short
contact time (0.25 s) and low indentation force (50 pN) to
ensure that we were measuring single bonds (see Methods).
In control experiments, adhesion frequency was reduced fur-
ther by 66% in the presence of an antibody directed against
domain 2 of JAMA and by 70% with the TS1/22 antibody
against LFA-1. Adhesion was not supported for Jurkat cells
on BSA. Unbinding forces for LFA-1/JAM-A were com-
piled into force histograms, and, as described previously,
the peak forces were plotted for a loading rate range of
~500–60,000 pN/s to generate the dynamic force spectrum
shown in Fig. 5 D. The average unbinding force increased
with the loading rate. The dynamic force spectrum of the
LFA-1/JAM-A interaction was overlaid with that of JAM-
A/JAM-A demonstrating that the unbinding forces were sig-
nificantly higher for the LFA-1/JAM-A interaction (Fig. 5
D). Our results indicate that the LFA-1/JAM-A interaction
is better able to resist pulling forces than the JAM-A/JAM-
A interaction, thus ensuring the likelihood that leukocyte
TEM will proceed.
DISCUSSION
The process of leukocyte homing involves leukocyte rolling
and crawling on the endothelium, firm adhesion and, finally,
TEM. During TEM, a possibility exists for the formation of
a trimeric complex between LFA-1 on the migrating leuko-
cyte, JAM-A on the endothelial cell, and a second JAM-A
receptor on the opposing endothelial cell (18). One of these
interactions has to be disrupted for the leukocyte to continue
to migrate into the endothelial junction. Our data support
a TEM model in which LFA-1 expressed on the surface of
a migrating leukocyte weakens the junctional JAM-A homo-
philic interaction by binding to the membrane-proximal
second Ig domain of JAM-A. LFA-1 is carrying out a dual
purpose: it allows the migrating leukocyte to be recruited
into the endothelial cell junction, and it blocks the second
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JAM-A homophilic interaction. The weakened JAM-A inter-
action is likely to be disrupted, whereas the stronger LFA-1/
JAM-A interaction remains and so allows the leukocyte to
proceed farther down the endothelial junction.
Our results indicate that the second Ig domain of JAM-A
is important for stabilizing its homophilic interaction. This
was first shown in solid-phase binding assays conducted to
compare the effectiveness of JAM-A and JAM-A$D1 as spe-
cific binding inhibitors for the JAM-A homophilic interac-
tion. These assays revealed that the JAM-A mutant lacking
the second domain of JAM-A could not compete for
JAM-A binding as effectively as full-length JAM-A (Fig. 1).
Further evidence indicating the importance of the second do-
main of JAM-A was obtained in the single-molecule AFM
adhesion measurements of the JAM-A/JAM-A$D1 interac-
tion in which significantly lower adhesion forces were mea-
sured than for the JAM-A/JAM-A interaction (Fig. 2 C). The
greater adhesion forces measured for the JAM-A/JAM-A
interaction were not the result of the second domain binding
to either domain of JAM-A. Single-molecule adhesion mea-
surements conducted with JAM-A/JAM-A$D2, JAM-A$D1/
JAM-A$D2, and JAM-A$D2/JAM-A$D2 did not reveal any
specific interaction of the second domain with either itself or
the first domain. The second domain must therefore be stabi-
lizing the JAM-A homophilic interaction, and its absence re-
sults in a reduction of measured adhesion forces. This finding
has been demonstrated for another Ig superfamily member,
namely, ICAM-1, in which the first Ig domain is involved
in ligand binding and the second Ig domain stabilizes this
binding (34). Therefore, by occupying the second domain
of JAM-A, LFA-1 may be destabilizing the homophilic
JAMA interactions, thus acting to loosen the junctional
contacts and allowing leukocyte TEM to proceed.
This model is also supported by subsequent experimental
data, which revealed that the binding of LFA-1 weakened
the JAM-A homophilic interaction. Binding of the LFA-1
I-domain to JAM-A reduced the dynamic strength of the
JAM-A homophilic interaction to the level measured with
JAM-A$D1, which suggests that the binding of LFA-1
canceled the stabilizing effects of the second Ig domain of
JAM-A (Fig. 4). Furthermore, our single-molecule adhesion
measurements indicate that the interaction of LFA-1 with
JAM-A is stronger or more resistant to pulling forces than
the JAM-A homophilic interaction. This observation was
evidenced by the overall lower unbinding forces measured
for the JAM-A homophilic interaction compared to the
LFA-1/JAM-A interaction. In addition, the dynamic force
spectrum of the LFA-1/JAM-A interaction shown in Fig. 5
D exhibits two loading rate regimes. Complexes with two
loading rate regimes are better able to resist pulling forces
because their disruption requires overcoming two activation
barriers. This finding was demonstrated for a number of in-
teractions, including LFA-1/ICAM-1 and LFA-1/ICAM-2
(29,30). In contrast, the dynamic force spectrum of theJAM-A homophilic interaction exhibits a single regime, sug-
gesting that only a single activation barrier would need to be
overcome for the JAM-A/JAM-A interaction to be disrupted.
Therefore, the heterophilic interaction is overwhelmingly the
stronger and more stable one.
It is important to note that the homophilic interaction of
JAM-A can take place in trans, which allows for JAM-A
receptors to interact with those on opposing cells (i.e.,
‘‘across’’ the endothelial junction), or in cis, which leads to
dimer formation. Our data strongly suggest that we are mea-
suring the JAM-A interaction in trans. Histograms compil-
ing our measured JAM-A/JAM-A breakage forces did not
reveal two peaks of adhesion forces, which would be an
indication of two different types of JAM-A homophilic inter-
actions. The absence of two peaks is an indication that either
only one type of interaction was measured or that both the cis
and trans interactions exhibit very similar forces and there-
fore the two interaction types are not resolved. Based on
the most likely orientation of JAM-A receptors on the tip,
it is highly probable that only the trans interaction was
measured. Future studies conducted with JAM-A mutants
that are unable to form dimers could further substantiate
this claim. For this study, we chose not to fit the JAM-A
single-molecule adhesion data to a thermodynamic model
until the interaction type is confirmed.
The events of leukocyte trafficking have been the subject
of many previous studies, discussed below, that have also
relied on single-molecule force spectroscopy. A number of
studies (31,32,35,36) have focused on the important initial
step of this process, namely, leukocyte rolling, which is pri-
marily mediated by selectin/ligand interactions as well as the
integrin a4b1/VCAM-1 interaction. The subsequent firm ad-
hesion step, primarily mediated by the LFA-1/ICAM-1 inter-
action and the a4b1/VCAM-1 interaction, has also been ex-
tensively studied (29,30,37). The reported dissociation
rates for the unbinding of the selectin interactions were faster
and the interactions were more sensitive to pulling forces
than those formed between ICAM-1 and LFA-1. This finding
is consistent with their physiological functions, as selectin
interactions must be disrupted and reformed continuously
to maintain cell rolling, while the ICAM-1/LFA-1 interaction
is responsible for maintaining the firm adhesion of the leuko-
cyte to the endothelium. Although we cannot report the dis-
sociation rates and bond lifetimes for the JAM-A homophilic
interaction due to the limitation described previously, we can
note that these values for the LFA-1/JAM-A interactions
very closely match those reported for the LFA-1/ICAM-1 in-
teraction. This finding makes sense physiologically because
the LFA-1/JAM-A interaction may also maintain firm adhe-
sion on the endothelial surface before leukocyte transmigra-
tion. In terms of adhesion forces, the forces measured for the
JAM-A homophilic interaction are lower than those mea-
sured for both LFA-1/JAM-A and LFA-1/ICAM-1 interac-
tions. They are comparable to forces measured for another
interaction occurring between endothelial cells, namely,Biophysical Journal 96(1) 285–293
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and VE-cadherins (38,39). These results are all consistent
with the physiological process of leukocyte TEM. For the
cell to continue its migration across an endothelial junction,
it makes sense for the interactions that it forms with the junc-
tional receptors (i.e., LFA-1/JAM-A) to be stronger than those
formed between the receptors found within the junction.
Future studies should focus on both cis and trans JAM-A
interactions, because the weakening of both interactions may
play an important role in the process of loosening junctional
JAM-A contacts. Disrupting the homophilic JAM-A interac-
tions in trans would directly open the endothelial cell junc-
tion for the migrating cell. Disrupting the cis interaction
would disrupt the JAM-A dimers. Both the dimerization
and clustering of receptors have been shown to strengthen
cell adhesion (40–46). Therefore, it is possible that the
homophilic interaction of JAM-A dimers may be stronger
than that of JAM-A monomers, although this warrants
further investigation. In addition, JAM-A dimers have been
postulated to precede the formation of homophilic JAM-A
contacts in trans in vivo (13). If this hypothesis were true,
disruption of the dimers by LFA-1 would be a critical step
because it would prevent the formation of junctional JAM-A
homophilic contacts and keep the junction open for the
migrating cell. The actual TEM process could involve a
combination of these two mechanisms.
In summary, we present evidence that the second domain
of JAM-A is important for stabilizing the JAM-A homo-
philic interaction. Our results support a model for the early
events of TEM during which LFA-1 expressed on a leuko-
cyte interacts with a JAM-A homophilic complex formed
across the endothelial junction (trans). By binding to the sec-
ond domain of JAM-A, LFA-1 destabilizes the JAM-A
homophilic interaction. The already stronger LFA-1/JAM-A
interaction persists, whereas the JAM-A homophilic interac-
tion is disrupted, opening the junction and allowing the
leukocyte to migrate into the junction.
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